retatrutide clinical trial results 2024 2025 press release A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity | European Journal of Pharmacology June 8, 2026: Reckless physicians

US$ 22.78

★★★★★ 4.2 (7 reviews)

US$ 29.67

★★★★★ 4.7 (8 reviews)

US$ 27.59

★★★★★ 4.0 (23 reviews)

US$ 25.86

★★★★★ 4.5 (20 reviews)

US$ 26.37

★★★★★ 4.6 (18 reviews)

US$ 20.39

★★★★★ 4.0 (15 reviews)

US$ 23.98

★★★★★ 4.9 (5 reviews)

US$ 20.23

★★★★★ 4.8 (8 reviews)

US$ 23.67

★★★★★ 4.9 (28 reviews)

US$ 28.64

★★★★★ 4.5 (14 reviews)

US$ 20.93

★★★★★ 4.4 (16 reviews)

US$ 25.38

★★★★★ 4.2 (13 reviews)

US$ 24.82

★★★★★ 4.6 (10 reviews)

US$ 24.34

★★★★★ 4.9 (7 reviews)

US$ 21.07

★★★★★ 4.7 (5 reviews)

US$ 22.37

★★★★★ 5.0 (27 reviews)

US$ 29.71

★★★★★ 4.5 (27 reviews)

US$ 22.27

★★★★★ 4.1 (13 reviews)

US$ 24.74

★★★★★ 4.7 (27 reviews)

US$ 26.94

★★★★★ 4.3 (22 reviews)